Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BIV201 (terlipressin diacetate), a vasopressin agonist, it increases systemic vascular resistance, particularly in the splanchnic area, resulting in a decrease of portal pressure. It reduces ascites fluid buildup.
Brand Name : BIV201
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 13, 2023
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TERLIVAZ® (terlipressin), is the first and only FDA-approved product indicated to improve kidney function in adults with hepatorenal syndrome involving rapid reduction in kidney function,1 an acute and life-threatening condition requiring hospitalizatio...
Brand Name : Terlivaz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 03, 2022
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TERLIVAZ (terlipressin) is the first and only FDA-approved product indicated to improve kidney function in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function, an acute and life-threatening condition requiring hospitalization.
Brand Name : Terlivaz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 24, 2022
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Terlivaz (terlipressin) is the first and only FDA-approved product indicated to improve kidney function in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function, an acute and life-threatening condition requiring hospitalization.
Brand Name : Terlivaz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2022
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Teripress (Terlipressin) is an analogue of vasopressin used as a vasoactive drug in the management of hypotension which has been found to be effective when norepinephrine fails.
Brand Name : Teripress
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 23, 2022
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201
Details : BIV201 (continuous infusion terlipressin), drug used in over 40 countries to treat related complications of liver cirrhosis appears to reduce ascites fluid build-up and may extend the period of time between required paracenteses.
Brand Name : BIV201
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 23, 2022
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Teripress (Terlipressin) is an investigational agent, to treat adults with hepatorenal syndrome (HRS) involving rapid reduction in kidney function, an acute and life-threatening condition.
Brand Name : Teripress
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 13, 2022
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Mallinckrodt Provides a Regulatory Update on Terlipressin
Details : U.S. FDA issued a CRL regarding the Company's NDA seeking approval for Teripress (terlipressin) to treat adults with hepatorenal syndrome, an acute and life-threatening syndrome and its safety and effectiveness have not yet been established by FDA.
Brand Name : Teripress
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 22, 2022
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A subsequent randomized, controlled Phase 2b trial with target enrollment of 30 subjects is currently underway, with 20 refractory ascites patients expected to receive BIV201 therapy compared to 10 patients who will receive standard-of-care (regular para...
Brand Name : BIV201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 04, 2021
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Terlipressin is one of the accepted vasoactive therapies recommended by the European Association for the Study of the Liver guidelines, which recommends that vasoconstrictive therapy should be initiated as soon as acute variceal bleeding is suspected and...
Brand Name : Teripress
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 25, 2021
Lead Product(s) : Terlipressin Acetate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?